Serocit-46.7% Injection 5 ml

Serocit-46.7% Injection 5 ml is used as an anticoagulant solution to reduce the risk of infection and prevent the formation of thrombus within the catheter. It is recommended for patients with central venous catheters. Central venous catheters are thin tubes inserted into large veins to administer medications, fluids, or blood, and they are often used for long-term treatment.

Serocit-46.7% Injection 5 ml contains Trisodium Citrate (TSC). It prevents coagulation by chelation of ionized calcium in the extracorporeal circuit, which stops the activation of coagulation factors and fibrin formation. It does not cause systemic anticoagulation and also helps reduce biofilms by binding to calcium.

A healthcare professional will administer Serocit-46.7% Injection 5 ml. Serocit-46.7% Injection 5 ml is not known to cause any side effects when used as a catheter lock. However, if the solution accidentally enters the intravenous line, it may result in paresthesia (numbness) or dysgenesis. These effects are usually linked to accidental exposure and should be monitored closely.

Serocit-46.7% Injection 5 ml is only for use as a catheter lock solution. It is contraindicated in patients who are allergic to polyhexanide or chlorhexidine, as it may trigger an anaphylactic reaction. If patients are receiving drugs through the catheter and there are known interactions with citrate or PHMA (like coagulation factor treatments), the catheter should be flushed with isotonic saline before the catheter lock procedure.

Serocit-46.7% Injection 5 ml is used to prevent blood clotting during granulocytapheresis procedures (granulocyte collection by apheresis). The detailed uses of Serocit-46.7% Injection 5 ml are as follows:

• Anticoagulant for apheresis:Serocit-46.7% Injection 5 ml helps maintain blood fluidity during granulocyte collection by preventing clot formation.Ensures safe cell separation:Serocit-46.7% Injection 5 ml supports effective separation and collection of granulocytes by reducing clotting risks during the procedure.

• Serocit-46.7% Injection 5 ml is administered by the doctor or nurse in a healthcare setting.
• Do not self-administer.

Serocit-46.7% Injection 5 ml is a catheter locking solution that prevents blood clots in any type of intravenous catheter. It contains Trisodium Citrate (TSC), which acts as an anticoagulant by chelating ionized calcium in the extracorporeal circuit, forming a soluble complex. Calcium plays an essential role in the coagulation process, and its removal by citrate prevents the activation of coagulation factors like factor X and prothrombin, thus inhibiting fibrin formation. This process does not cause systemic anticoagulation. Additionally, TSC helps reduce biofilms by binding and neutralizing calcium (Ca2+) in the surroundings.

Serocit-46.7% Injection 5 ml should be administered only by trained personnel. It should not be injected directly into the intravenous route or mixed with an infusion. Always verify the correct catheter volume according to the manufacturer's guidelines. Do not exceed the recommended catheter volume. Avoid contact with eyes or open wounds. It is contraindicated in patients who are allergic to polyhexanide or chlorhexidine, as it may trigger an anaphylactic reaction. Serocit-46.7% Injection 5 ml should not be re-sterilized or used after its expiration date. Always use proper aseptic techniques when applying the locking solution to prevent introducing infection into the catheter.